

Resource Summary Report

Generated by [NIF](#) on Sep 14, 2026

Panc 08.13

RRID:CVCL_1638

Type: Cell Line

Proper Citation

RRID:CVCL_1638

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1638

Proper Citation: RRID:CVCL_1638

Description: Cell line Panc 08.13 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:9612602](#), [PMID:14695172](#), [PMID:16912165](#), [PMID:18000365](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22753594](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Johns Hopkins University School of Medicine; Baltimore; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Panc 08.13

Synonyms: Panc 8.13, Panc-08.13, PANC-08-13, Panc_08_13, Panc08.13, Panc8.13, Panc-8_13, Panc-813, PANC 813, Panc813, PANC813, PANC0813, Panc0813, Pa14C, PL9, PL-9

Cross References: CLO:CLO_0008379, EFO:EFO_0006470, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-

3610, ATCC:CRL-2551, BioGRID_ORCS_Cell_line:189, BioSample:SAMN03472947, BioSample:SAMN10988145, cancercellines:CVCL_1638, Cell_Model_Passport:SIDM01136, ChEMBL-Cells:ChEMBL3308777, ChEMBL-Targets:ChEMBL1075558, Cosmic:925347, Cosmic:949526, Cosmic:1198215, Cosmic:1198221, Cosmic:1473126, Cosmic:1509858, Cosmic:2434104, Cosmic-CLP:925347, DepMap:ACH-000417, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:925347, GEO:GSM206531, GEO:GSM621905, GEO:GSM784709, GEO:GSM827278, GEO:GSM887499, GEO:GSM888581, GEO:GSM1024410, GEO:GSM1374813, GEO:GSM1670334, LiGeA:CCLE_501, LINCS_LDP:LCL-1742, PharmacDB:Panc08_13_1244_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_1638, PubChem_Cell_line:CVCL_1638, Wikidata:Q54937528

ID: CVCL_1638

Record Creation Time: 20220427T221408+0000

Record Last Update: 20260913T005715+0000

Ratings and Alerts

No rating or validation information has been found for Panc 08.13.

No alerts have been found for Panc 08.13.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. Nature communications, 16(1), 10733.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. Cancer research, 85(18), 3540.

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. Nature communications, 16(1), 4866.

Cao M, et al. (2025) PPY-Induced iCAFs Cultivate an Immunosuppressive Microenvironment in Pancreatic Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(20), e2413432.

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degradator of the Nuclear Pore Complex. *Cancer discovery*, 15(12), 2505.

Yu J, et al. (2024) Ultra-large scale virtual screening identifies a small molecule inhibitor of the Wnt transporter Wntless. *iScience*, 27(8), 110454.

Vogt M, et al. (2024) Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2. *Gut*, 73(9), 1509.

Stalneck CA, et al. (2022) Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. *Cancer research*, 82(4), 586.

Krenz B, et al. (2021) MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. *Cancer research*, 81(16), 4242.